No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols (Q44494660)

3 December 2017

title

No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols (English)

1 reference

3 December 2017

J B Engel

1

1 reference

3 December 2017

M Ludwig

2

1 reference

3 December 2017

K Junge

3

1 reference

3 December 2017

C M Howles

4

1 reference

3 December 2017

K Diedrich

5

1 reference

3 December 2017

publication date

1 June 2003

1 reference

Reproductive BioMedicine Online

3 December 2017

published in

1 reference

3 December 2017

volume

6

1 reference

3 December 2017

issue

4

1 reference

3 December 2017

page(s)

482-487

1 reference

Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

The role of LHRH agonists and antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Comment on the debate article: embryo implantation: the Rubicon for GnRH antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Gonadotrophin-releasing hormone antagonists: will they replace the agonists?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

The place of gonadotrophin-releasing hormone antagonists in reproductive medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Extremes of body mass do not adversely affect the outcome of superovulation and in-vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Plasma and follicular fluid concentrations of LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for IVF.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Safety aspects of gonadotrophin-releasing hormone antagonists in ovarian stimulation procedures: ovarian hyperstimulation syndrome and health of children born.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

GnRH antagonists: do they open new pathways to safer treatment in assisted reproductive techniques?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

Does body mass index of infertile women have an impact on IVF procedure and outcome?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962171-2

7 January 2021

10.1016/S1472-6483(10)62171-2

Identifiers

DOI

1 reference

3 December 2017

1 reference